Published online May 28, 2017. doi: 10.3748/wjg.v23.i20.3632
Peer-review started: February 2, 2017
First decision: March 3, 2017
Revised: March 21, 2017
Accepted: May 4, 2017
Article in press: May 4, 2017
Published online: May 28, 2017
Processing time: 120 Days and 3.8 Hours
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world. The incidence and mortality show wide geographical variations. Screening is recommended to reduce both incidence and mortality. However, there are significant differences among studies in implementation strategies and detection. This review aimed to present the results and strategies of different screening programs worldwide. We reviewed the literature on national and international screening programs published in PubMed, on web pages, and in clinical guidelines. CRC Screening programs are currently underway in most European countries, Canada, specific regions in North and South America, Asia, and Oceania. The most extensive screening strategies were based on fecal occult blood testing, and more recently, the fecal immunochemical test (FIT). Participation in screening has varied greatly among different programs. The Netherlands showed the highest participation rate (68.2%) and some areas of Canada showed the lowest (16%). Participation rates were highest among women and in programs that used the FIT test. Men exhibited the greatest number of positive results. The FIT test has been the most widely used screening program worldwide. The advent of this test has increased participation rates and the detection of positive results.
Core tip: Colorectal cancer is the third most commonly diagnosed cancer worldwide. The incidence and mortality show wide geographical variations across the world. Screening is recommended to reduce both, however, there are significant differences among studies in implementation strategies and detection. This review aimed to present the results and strategies of different screening programs worldwide.